Ernexa Therapeutics (ERNA) Stock Price, Financials & Analysis

Key Stats

Market Cap3.31 Mn

P/E-0.22

FCF (Yr)-7.05 Mn

ROA (Yr)-253.70

EV to EBIT1.25

Net Income (Yr)-14.10 Mn

Enterprise Value-18.41 Mn

Add ratio to table…

About

Ernexa Therapeutics Inc. is a preclinical stage synthetic allogeneic iMSC therapy company focused on developing off the shelf cell therapies for cancer and autoimmune diseases using induced pluripotent stem cell derived mesenchymal stem cells. The company generates revenue primarily through potential future product sales, licensing agreements, and collaborations, including upfront and milestone payments from partners such as Factor Bioscience Limited under its exclusive…

How Ernexa Therapeutics ranks

Ranked against the 695 companies in Pharmaceuticals and Biotechnology58 metrics · as of Nov 11, 2026

Valuation

12 metrics · Lower multiples rank higher; a negative multiple ranks last

P/ENegative earnings −0.22xMedian 16.3x 10^th
P/FCFNegative free cash flow −0.31xMedian 18.3x 9^th
P/Operating cash flowNegative operating cash flow −0.31xMedian 16.4x 9^th
P/S 38.9xMedian 8.76x 27^th
P/B 0.76xMedian 2.18x 79^th
P/Tangible book 0.76xMedian 2.42x 82^nd
EV/EBITDANet cash exceeds market value 0.16xMedian 15.5x Not meaningful —
EV/EBITNet cash exceeds market value 0.16xMedian 18.2x Not meaningful —
EV/RevenueNet cash exceeds market value −27.0xMedian 6.49x Not meaningful —
EV/FCFNet cash exceeds market value 0.21xMedian 21.2x Not meaningful —
EV/Operating cash flowNet cash exceeds market value 0.21xMedian 17.0x Not meaningful —
PEG (3Y EPS CAGR)Negative earnings 0.00Median 0.40 Not meaningful —

Growth

14 metrics · Year-on-year growth and three-year compound annual growth

Revenue growth (1Y) 54.5%Median 12.7% 70^th
Revenue CAGR (3Y) 4.3%Median 10.4% 40^th
Gross profit growth (1Y) —Median 11.8% No data —
Gross profit CAGR (3Y) —Median 12.0% No data —
Operating income growth (1Y) −49.0%Median −2.8% 23^rd
Operating income CAGR (3Y) 9.8%Median 1.6% 62^nd
Net income growth (1Y) 23.8%Median −4.4% 73^rd
Net income CAGR (3Y) 11.3%Median 0.3% 62^nd
EPS growth (1Y) −301%Median 23.6% 7^th
EPS CAGR (3Y) 45.6%Median 26.4% 72^nd
Operating cash flow growth (1Y) −14.2%Median −1.2% 39^th
Operating cash flow CAGR (3Y) 20.2%Median 2.0% 76^th
Free cash flow growth (1Y) −14.4%Median −1.5% 39^th
Free cash flow CAGR (3Y) 20.2%Median 2.8% 74^th

Profitability

14 metrics · Margins, returns on capital and the quality of earnings

Gross margin —Median 73.6% No data —
EBITDA margin <−10,000%Median −258% 4^th
Operating margin <−10,000%Median −268% 5^th
Pretax margin <−10,000%Median −252% 5^th
Net margin <−10,000%Median −239% 5^th
FCF margin <−10,000%Median −205% 5^th
Operating cash flow margin <−10,000%Median −202% 5^th
Return on equity −370%Median −56.5% 7^th
Return on assets −208%Median −41.6% 9^th
Return on invested capital —Median −7.2% No data —
Return on capital employed −361%Median −47.7% 6^th
Asset turnover 0.01xMedian 0.17x 14^th
Cash conversion (OCF / net income)Net income is not positive 0.77xMedian 1.02x Not meaningful —
Stock comp / revenue 1,575%Median 37.0% 7^th

Financial Health

11 metrics · Leverage, liquidity and solvency; less debt ranks higher

Debt / assets —Median 17.2% No data —
Debt / equity —Median 0.21x No data —
Net debt / EBITDA —Median 1.21x No data —
Debt / FCF —Median 3.57x No data —
Liabilities / assets 38.8%Median 32.8% 46^th
Equity / assets 61.2%Median 67.2% 46^th
Interest coverage —Median −12.1x No data —
Current ratio 2.57xMedian 4.41x 34^th
Quick ratio 2.14xMedian 3.75x 35^th
Cash ratio 2.14xMedian 3.34x 40^th
Altman Z-score −56.3Median −0.77 5^th

Shareholder Returns

7 metrics · Cash returned through dividends and buybacks; a lower payout ranks higher

Dividend yield —Median 2.3% No dividend —
Net buyback yieldAbove 100% of market value −289%Median −3.4% Not meaningful —
Shareholder yieldAbove 100% of market value −289%Median −2.3% Not meaningful —
Payout ratio (earnings) —Median 79.0% No dividend —
Payout ratio (FCF) —Median 56.7% No dividend —
Dividend growth (1Y) —Median 2.9% No dividend —
Dividend CAGR (3Y) —Median 3.6% No dividend —

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	LLY	ELI LILLY & Co	1,348.13 Bn	46.34	15.59	49.50 Bn
2	JNJ	Johnson & Johnson	675.90 Bn	42.03	6.80	44.65 Bn
3	ABBV	AbbVie Inc.	519.45 Bn	50.27	7.87	80.90 Bn
4	MRK	Merck & Co., Inc.	364.95 Bn	148.95	5.42	53.78 Bn
5	NVS	Novartis Ag	311.58 Bn	17.91	5.08	-
6	AZN	Astrazeneca Plc	289.34 Bn	26.23	4.87	-6.68 Bn
7	AMGN	Amgen Inc	251.64 Bn	26.80	6.47	54.01 Bn
8	ERNA	Ernexa Therapeutics Inc.	0.00 Bn	-0.22	38.90	-

S.No.

Ticker

Company

Market Cap

P/E

P/S

Total Debt (Qtr)

LLY

ELI LILLY & Co

1,348.13 Bn

46.34

15.59

49.50 Bn

JNJ

Johnson & Johnson

675.90 Bn

42.03

6.80

44.65 Bn

ABBV

AbbVie Inc.

519.45 Bn

50.27

7.87

80.90 Bn

MRK

Merck & Co., Inc.

364.95 Bn

148.95

5.42

53.78 Bn

NVS

Novartis Ag

311.58 Bn

17.91

5.08

AZN

Astrazeneca Plc

289.34 Bn

26.23

4.87

-6.68 Bn

AMGN

Amgen Inc

251.64 Bn

26.80

6.47

54.01 Bn

ERNA

Ernexa Therapeutics Inc.

0.00 Bn

-0.22

38.90

Ernexa Therapeutics ERNA

About

Products and Services Breakdown of Revenue (2020)

Statement Geographical Breakdown of Revenue (2020)

How Ernexa Therapeutics ranks

Valuation

Growth

Profitability

Financial Health

Shareholder Returns

Peer Comparison

Ernexa Therapeutics ERNA

About

Products and Services Breakdown of Revenue (2020)

Statement Geographical Breakdown of Revenue (2020)

How Ernexa Therapeutics ranks

Valuation

Growth

Profitability

Financial Health

Shareholder Returns

Peer Comparison

Create an account

Sign In

Reset Password